Flortaucipir

Summary

Flortaucipir (CHEMBL3546271) is an approved small molecule; indicated across 1 condition including alzheimer disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 6
• Chemistry: 263.27 Da · C16H10FN3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3546271
Name	Flortaucipir
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	71059746
Molecular formula	C16H10FN3
Molecular weight	263.27
InChIKey	GETAAWDSFUCLBS-UHFFFAOYSA-N

SMILES: C1=CC2=C(C=C1C3=CN=C(C=C3)F)NC4=C2C=NC=C4

IUPAC name: 7-(6-fluoro-3-pyridinyl)-5H-pyrido[4,3-b]indole

Also known as: Flortaucipir, T-807, T807, FLORTAUCIPIR, FLORTAUCIPIR F 18

Parent form; salt/anhydrous children: CHEMBL3545253

Patent coverage: 93 distinct patent families (243 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 195 (80%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	1	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
Not specified	3
PHASE3	1
EARLY_PHASE1	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03901092	PHASE3	COMPLETED	A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation
NCT04263337	PHASE1	ACTIVE_NOT_RECRUITING	NFL LONG Prospective Study
NCT01733355	EARLY_PHASE1	TERMINATED	A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807
NCT03507257	Not specified	RECRUITING	Longitudinal Early-onset Alzheimer’s Disease Study Protocol
NCT06690983	Not specified	RECRUITING	Tau PET/CT in Various Tau-Related Disease Patients
NCT01231971	Not specified	COMPLETED	Alzheimer’s Disease Neuroimaging Initiative 2

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).